It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
The crystalline landscape of a drug substance can dramatically affect development timelines, costs, and complexity.
While the most stable crystalline form is often preferred, identifying it is rarely straightforward. That’s where our thermodynamic expertise and advanced analytical tools come in, helping you mitigate risks and make informed decisions at every stage.
Our polymorph screening is tailored to your development stage and material constraints, combining systematic crystal form exploration with advanced solid-state techniques like XRPD, DSC, TGA, DVS, and NMR. This deep scientific approach reveals all viable forms, enabling confident selection of the most stable or phase-appropriate polymorph. From there, we support you with follow-on testing in stability, solubility, and dissolution, along with expert guidance on interconversion and long-term form stability. Whether you’re mitigating risk, preparing for regulatory submission, or strengthening formulation robustness, we help you move forward with clarity and confidence.
Why Choose Sygnature Discovery for Polymorph Screening Support?
We screen for a wide range of crystal forms – including anhydrous polymorphs, hydrates, and solvates – using varied solvents and experimental conditions. This comprehensive approach ensures that all potential forms are considered, including those that may emerge during manufacturing or storage. Identifying the thermodynamically stable or most phase-appropriate form is essential for formulation robustness throughout development. Beyond formulation, the polymorphic profile of your compound can also be a strategic asset for intellectual property. Sygnature Discovery delivers detailed solid-state characterization data (XRPD, DSC, TGA, DVS, NMR), to support:
• Patent applications
• Regulatory submissions (e.g., DMFs, INDs)
• Claims of novelty and utility
Core Analytical Techniques
XRPD Analysis
Confirm novelty of crystal form
TGA Analysis
Assess hydration and solvation
DSC Analysis
Profiles thermal behavior including
DVS Analysis
Evaluates hygroscopicity and hydration/dehydration behavior
Multinuclear NMR
Verifies chemical integrity and detects residual solvents
Delve into the realm of targeted protein degradation and the critical role of formulation strategies in drug development. From overcoming dissolution limitations to optimizing stability and solubility, explore the key components that ensure your molecule’s clinical success. Sygnature Discovery offers comprehensive formulation support, bringing your degrader one step closer to achieving its full potential.
Sygnature has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at…
News
FAQs
Different polymorphs can significantly impact :
• Formulation performance
• Manufacturing reproducibility
• Shelf-life stability
• Patentability and regulatory approval
Selecting the right polymorph is critical for ensuring consistent therapeutic outcomes.
Polymorphic transitions can lead to:
• Reduced efficacy
• Inconsistent bioavailability
• Regulatory non-compliance
Hence, polymorph stability is a key consideration during formulation and process development.
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
DMPK
Integrated DMPK solutions combining advanced assays, modeling, and bioanalysis delivering predictive insights that reduce risk and guide candidate selection.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
